Healthcare - Biotechnology - NASDAQ - CN
$ 1.11
11 %
$ 61.3 M
Market Cap
-2.85
P/E
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation.[ Read More ]
The intrinsic value of one CNTB stock under the base case scenario is HIDDEN Compared to the current market price of 1.11 USD, Connect Biopharma Holdings Limited is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart CNTB
FINANCIALS
0
REVENUE
-62.1 M
OPERATING INCOME
-59.4 M
NET INCOME
-47.9 M
OPERATING CASH FLOW
75.2 M
INVESTING CASH FLOW
-246 K
FINANCING CASH FLOW
12.1 M
REVENUE
3.65 M
OPERATING INCOME
7.65 M
NET INCOME
-3.99 M
OPERATING CASH FLOW
6.14 M
INVESTING CASH FLOW
-23 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Connect Biopharma Holdings Limited
| Current Assets | 121 M |
| Cash & Short-Term Investments | 119 M |
| Receivables | 51 K |
| Other Current Assets | 2.27 M |
| Non-Current Assets | 4.92 M |
| Long-Term Investments | 0 |
| PP&E | 4.73 M |
| Other Non-Current Assets | 194 K |
| Current Liabilities | 24.3 M |
| Accounts Payable | 7.66 M |
| Short-Term Debt | 285 K |
| Other Current Liabilities | 16.3 M |
| Non-Current Liabilities | 585 K |
| Long-Term Debt | 180 K |
| Other Non-Current Liabilities | 405 K |
EFFICIENCY
Earnings Waterfall
Connect Biopharma Holdings Limited
| Revenue | 0 |
| Cost Of Revenue | 988 K |
| Gross Profit | -988 K |
| Operating Expenses | 62.1 M |
| Operating Income | -62.1 M |
| Other Expenses | -2.69 M |
| Net Income | -59.4 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-58.89%
ROE
-47.27%
ROA
-61.56%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Connect Biopharma Holdings Limited
| Net Income | -59.4 M |
| Depreciation & Amortization | 988 K |
| Capital Expenditures | -294 K |
| Stock-Based Compensation | 3.26 M |
| Change in Working Capital | 9.48 M |
| Others | 10.4 M |
| Free Cash Flow | -48.2 M |
Wall Street Analysts Price Targets
Connect Biopharma Holdings Limited
CNTB has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Connect Biopharma Holdings Limited
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Attovia Therapeutics Appoints Chief Financial Officer
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer
globenewswire.com
- 1 month ago
CNTB Stock Surges Over 5% Amid Strong Financial Performance
Concordia Biotech (CNTB, Financial) saw a significant increase in its stock price, rising by 5.48%. The stock is currently priced at $1.49 per share with a trading volume of 16,435 shares and a turnover rate of 0.03%.
gurufocus.com
- 1 month ago
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases, today reported financial results for the six months ended June 30, 2024 and provided a business update.
globenewswire.com
- 2 months ago
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA.
globenewswire.com
- 4 months ago
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that the Board of Directors (Board), including all of the independent directors of the Board, granted to Barry Quart, Pharm.D., the Company's newly-appointed Chief Executive Officer, and David Szekeres, the Company's newly-appointed President, non-qualified stock option awards to purchase an aggregate of 2,658,734 ordinary shares and 1,772,489 ordinary shares, respectively, under the Connect Biopharma Holdings Limited 2024 Employment Inducement Incentive Award Plan (the Inducement Plan). The options were granted effective June 12, 2024 and have an exercise price of $1.77 per share (the closing price of Connect's ordinary shares on the grant date). The options vest over a period of four years, with 25% vesting on June 12, 2025 and the remaining shares vesting in equal monthly installments thereafter, subject to each executive's continued employment or service. The awards were granted as inducements material to Dr. Quart and Mr. Szekeres entering into employment with Connect in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 5 months ago
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointments of Barry Quart, Pharm.D., as Chief Executive Officer (CEO) and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors (Board).
globenewswire.com
- 5 months ago
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Edward Kerwin, M.D. presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.
globenewswire.com
- 5 months ago
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ATS 2024 International Meeting being held May 17-22, 2024 in San Diego, CA.
globenewswire.com
- 6 months ago
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
SAN DIEGO, CA and TAICANG, China, April 16, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported financial results for the year ended December 31, 2023, and provided a business update.
globenewswire.com
- 7 months ago
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference in a fireside chat on Thursday, March 28, 2024 at 4:00 p.m. ET. Please see below for additional details about the event and how to request a one-on-one meeting with management.
globenewswire.com
- 7 months ago
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointment of James Zuie-chin Huang, M.B.A., to its Board of Directors effective immediately. James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company.
globenewswire.com
- 9 months ago
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma.
globenewswire.com
- 11 months ago
8. Profile Summary
Connect Biopharma Holdings Limited CNTB
COUNTRY
CN
INDUSTRY
Biotechnology
MARKET CAP
$ 61.3 M
Dividend Yield
0.00%
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Contact
East R&D Building, Taicang, 215400
https://www.connectbiopharm.com
IPO Date
March 19, 2021
Employees
81
Officers
Dr. Barry D. Quart Pharm.D.
Chief Executive Officer & Director
Mr. Jiang Bian J.D.
General Counsel & Chief Compliance Officer
Dr. Zheng Wei Ph.D.
Co-Founder & Director
Dr. Wubin Pan M.B.A., Ph.D.
Co-Founder & Director
Dr. Lei Sun Ph.D.
Vice President of Biologics & Head of CMC
Dr. Raul Collazo Ph.D.
Vice President & Global Head of Medical Affairs
Dr. Srikanth Pendyala M.D.
Senior Vice President of Clinical Development(Consultant)